SL
Silexion Therapeutics Ltd.
SLXNW · NASDAQ
$0.01 -62.50% (-$0.02)
1M -40.00%
Market Cap $6.73K
P/E Ratio -
Div. Yield -
ROE 276.59%
Bulios Fair Price
$0.01
16.7% downside
Current Price
$0.012
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SLXNW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.15x
PEG N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
40 /100
Average ROA 161.47%
ROIC 628.40%
Asset turnover 0.00x
Debt
8 /100
High Int. coverage -2,346.83x
Debt/Equity 32.05x
Current ratio 0.94x
Stability
19 /100
Unstable Profitable years 0
Beta -0.27x
EPS volatility 7,313.59%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SLXNW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Ilan Hadar
Employees
14
Headquarters
Jerusalem
Upcoming events
18 NOV
Earnings
Upcoming earnings report